Understanding the Burden of Primary Hyperoxaluria Type 1 (PH1)

Alnylam wanted to better characterize PH1 natural history in terms of clinical manifestations, interventions, and resource use events that contribute to disease burden throughout the patent journey. This one-pager breaks down the key findings from this important research.